Andera and LSP lead $84m series-B for Artios

New investors Pfizer Ventures and Novartis Venture Fund (NVF) also took part in the round alongside existing backers Arix Bioscience, SV Health Investors, M Ventures, IP Group and Abbvie Ventures.

The company will look to undertake clinical proof-of-concept trials for its programme targeting DNA polymerase theta.

Andera partner Raphael Wisniewski, LSP managing partner Rene Kuijten and Pfizer Ventures vice-president Barbara Dalton will take on director roles on the Artios board, while NVF principal Florian Muellershausen will join as an observer.

Previous funding
Imperial Innovations and SV Life Sciences took part in a £25m series-A for Artios in September 2016, alongside Abbvie, Merck Ventures, Arix and Sixth Element Capital. Imperial invested £5.1m for a 14.9% stake in the company.

Company
Founded in 2016 as a spinout from Cancer Research UK, Cambridge-headquartered Artios is a biotechnology company focusing on the development of DNA damage-response programmes for the treatment of cancers.

People
Andera Partners – Raphael Wisniewski (partner).
Life Sciences Partners – Rene Kuijten (managing partner).
Artios Pharma – Niall Martin (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture
• Andera Partners
• Life Science Partners